AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Teva Pharmaceutical Industries Ltd. M&A Activity 2006

Jan 10, 2006

7082_rns_2006-01-10_d8e0bf10-ce0b-4b0d-a93f-70ca2a0e9d54.htm

M&A Activity

Opens in your device viewer


C002	�� "�		2
Public	TEVA- PHARMACEUTICAL INDUSTRIES LTD.
	2529	Corporation no: 520013954
	Stock Exchange/Market: ��

	310
	380	P.O.B 3190 , Petach Tikva 49131 , ,
	Tel: 03-9267297 , 03-9267281 Fax: 03-9267429
	E.mail address: [email protected]	Date of transmission: 10/01/2006

		Time of broadcast: 17:22 16:35:13
		Reference: 2006-02-008196



Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000


The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on Teva and IVAX Announce that FTC Review Process Continues on Track and Merger Closing is Expected Shortly
TevaIvaxPressReleasereFTCReview_ClosingEFinal100106_isa.pdf


Please find attached a Press Release and it's non-binding hebrew translation provided for convenience puposes only.
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):

Previous names of reporting entity:
Date of revision of form structure: 28/12/2005
- - -
Name of the Signatory : Suesskind Dan , , Position of Signatory in the reporting corporation: Chief Financial Officer
Basel Telephone: 02-5892840 , Facsimile: 02-5892839 , E-mail: [email protected]